A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Seagen
- 07 Feb 2025 Planned number of patients changed from 140 to 142.
- 07 Feb 2025 Planned primary completion date changed from 31 Oct 2025 to 31 Dec 2025.
- 07 Feb 2025 Status changed from recruiting to active, no longer recruiting.